SocialPicks Monitor new  |    Stock Idea Community
SocialPicks
   Sign Up   |   Log In   |   What is SocialPicks?     
The Rock-Star Investors Next Door
SocialPicks is a community where stock investors exchange ideas and track performance of financial bloggers.
Top_member_photos
Get free stock picks and email alerts daily
 
Are you a stock guru?

0 pt

Opinion on  GlaxoSmithKline plc (GSK)     Sector: Healthcare  >  Industry: Major Drugs
Bullish on GSK ...

Oct 11, 2008 12:35 AM UTC
Rxlogo
Return Risk
-2.97% MID
Principal

GSK:  This call was made on 10/11/08 @ $36.18
Rating:   Positive   $36.18 (10/11/08)
Closed:   11/07/2008 @ $38.39 (+6.11% in 27 days)


Add Comment

Be the first to comment on this story and earn 2 points.

Your Comment



ROCK-STAR INVESTORS
Rank Name Sharpe Ratio Avg Return Followers
1 noshoes 18.70 +40.85% 174
2 Gerald Greene 17.51 +40.49% 57
3 krprasad 16.70 +18.24% 7
4 The Big Bear 14.22 +37.54% 211
5 akiralegrand 13.70 +16.71% 40


POPULAR STOCKS
Symbol Company Name Sentiment
V Visa Inc
AMD Advanced Micro Devices Inc
MO Altria Group Inc
JPM JPMorgan Chase & Co
POT Potash Corp. of Saskatchewan Inc.
IBM International Business Machines Corp

TODAY'S HEADLINES

TODAY'S TOP PICKS

 
GlaxoSmithKline plc (GSK)
   SocialPicks Sentiment:   

   This Quarter's Sentiment:
All:
82.5%
Top:
14.0%




Latest Picks by Mike Havrilla
Symbol SP Sentiment Rating Return Since
AMAG Positive -2.98% 11/30/08
KG Positive -1.07% 11/30/08
MEDX Positive -0.95% 11/30/08
JNJ Positive -0.43% 11/30/08
GENZ Positive -2.36% 11/30/08

View All >
   
Mike Havrilla previously rated GSK
Positive -2.32% Achillion Pharma: Funding in Place to Advance HCV Pipeline
11/25/2008
9
Positive +2.71% Updated FDA Calendar of 73 Decision Dates
11/22/2008
9
Positive -5.97% Updated FDA Calendar of Decision Dates
11/13/2008
9
Positive -7.01% A Backlog of Decisions is Building at the FDA
11/07/2008
9
Positive -18.79% Full FDA Calendar of Decision Dates
09/25/2008
3





IN THE PRESS
Press_forbes Press_washingtonpost Press_wsj Press_npr Press_techcrunch